rTMS Induces Brain Functional and Structural Alternations in Schizophrenia Patient With Auditory Verbal Hallucination.
MCCB
amplitude of low-frequency fluctuation
auditory verbal hallucination
schizophrenia
transcranial magnetic stimulation
voxel-based morphometry
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2021
accepted:
12
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Low-frequency transcranial magnetic stimulation (rTMS) over the left temporoparietal cortex reduces the auditory verbal hallucination (AVH) in schizophrenia. However, the underlying neural basis of the rTMS treatment effect for schizophrenia remains not well understood. This study investigates the rTMS induced brain functional and structural alternations and their associations with clinical as well as neurocognitive profiles in schizophrenia patients with AVH. Thirty schizophrenia patients with AVH and thirty-three matched healthy controls were enrolled. The patients were administered by 15 days of 1 Hz rTMS delivering to the left temporoparietal junction (TPJ) area. Clinical symptoms and neurocognitive measurements were assessed at pre- and post-rTMS treatment. The functional (amplitude of low-frequency fluctuation, ALFF) and structural (gray matter volume, GMV) alternations were compared, and they were then used to related to the clinical and neurocognitive measurements after rTMS treatment. The results showed that the positive symptoms, including AVH, were relieved, and certain neurocognitive measurements, including visual learning (VisLearn) and verbal learning (VerbLearn), were improved after the rTMS treatment in the patient group. Furthermore, the rTMS treatment induced brain functional and structural alternations in patients, such as enhanced ALFF in the left superior frontal gyrus and larger GMV in the right inferior temporal cortex. The baseline ALFF and GMV values in certain brain areas (e.g., the inferior parietal lobule and superior temporal gyrus) could be associated with the clinical symptoms (e.g., positive symptoms) and neurocognitive performances (e.g., VerbLearn and VisLearn) after rTMS treatment in patients. The low-frequency rTMS over the left TPJ area is an efficacious treatment for schizophrenia patients with AVH and could selectively modulate the neural basis underlying psychiatric symptoms and neurocognitive domains in schizophrenia.
Sections du résumé
BACKGROUND
BACKGROUND
Low-frequency transcranial magnetic stimulation (rTMS) over the left temporoparietal cortex reduces the auditory verbal hallucination (AVH) in schizophrenia. However, the underlying neural basis of the rTMS treatment effect for schizophrenia remains not well understood. This study investigates the rTMS induced brain functional and structural alternations and their associations with clinical as well as neurocognitive profiles in schizophrenia patients with AVH.
METHODS
METHODS
Thirty schizophrenia patients with AVH and thirty-three matched healthy controls were enrolled. The patients were administered by 15 days of 1 Hz rTMS delivering to the left temporoparietal junction (TPJ) area. Clinical symptoms and neurocognitive measurements were assessed at pre- and post-rTMS treatment. The functional (amplitude of low-frequency fluctuation, ALFF) and structural (gray matter volume, GMV) alternations were compared, and they were then used to related to the clinical and neurocognitive measurements after rTMS treatment.
RESULTS
RESULTS
The results showed that the positive symptoms, including AVH, were relieved, and certain neurocognitive measurements, including visual learning (VisLearn) and verbal learning (VerbLearn), were improved after the rTMS treatment in the patient group. Furthermore, the rTMS treatment induced brain functional and structural alternations in patients, such as enhanced ALFF in the left superior frontal gyrus and larger GMV in the right inferior temporal cortex. The baseline ALFF and GMV values in certain brain areas (e.g., the inferior parietal lobule and superior temporal gyrus) could be associated with the clinical symptoms (e.g., positive symptoms) and neurocognitive performances (e.g., VerbLearn and VisLearn) after rTMS treatment in patients.
CONCLUSION
CONCLUSIONS
The low-frequency rTMS over the left TPJ area is an efficacious treatment for schizophrenia patients with AVH and could selectively modulate the neural basis underlying psychiatric symptoms and neurocognitive domains in schizophrenia.
Identifiants
pubmed: 34539338
doi: 10.3389/fnins.2021.722894
pmc: PMC8441019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
722894Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Xie, Guan, Wang, Ma, Wang, Fang and Yin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Psychol Med. 2015 Jan;45(1):1-9
pubmed: 25065902
Psychiatry Res. 2000 Nov 20;100(1):13-20
pubmed: 11090721
Lancet. 1995 Sep 2;346(8975):596-600
pubmed: 7651003
Schizophr Res. 2008 Feb;99(1-3):304-11
pubmed: 18178386
Neuropsychobiology. 2020;79(6):384-396
pubmed: 31505508
J Psychiatry Neurosci. 2019 Oct 03;45(1):55-68
pubmed: 31580042
Biol Psychiatry. 2013 Mar 15;73(6):510-7
pubmed: 23039931
Schizophr Res. 2007 Dec;97(1-3):215-25
pubmed: 17851044
Neuroimage. 2012 Feb 1;59(3):2196-207
pubmed: 22008374
Psychiatry Res. 2007 May 15;155(1):83-8
pubmed: 17398078
Schizophr Bull. 2020 Mar 17;:
pubmed: 32185388
Neuroinformatics. 2016 Jul;14(3):339-51
pubmed: 27075850
Biol Psychiatry. 2013 May 15;73(10):1008-14
pubmed: 23485015
Psychol Med. 2010 Nov;40(11):1759-65
pubmed: 20624327
Eur Neurol. 2004;51(2):115-7
pubmed: 14963385
Schizophr Res Cogn. 2021 Feb 25;24:100195
pubmed: 33718008
Neuroimage. 2013 Sep;78:46-58
pubmed: 23587692
Schizophr Res Treatment. 2011;2011:581686
pubmed: 22937268
Can J Psychiatry. 2008 Sep;53(9):577-86
pubmed: 18801220
Schizophr Res. 2016 Dec;178(1-3):86-93
pubmed: 27613508
Schizophr Res. 2013 Oct;150(1):107-13
pubmed: 23911258
Am J Psychiatry. 2004 Sep;161(9):1603-11
pubmed: 15337650
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
Am J Psychiatry. 2013 Nov;170(11):1308-16
pubmed: 23732942
Schizophr Res. 2020 Aug;222:335-341
pubmed: 32423702
Mol Psychiatry. 2010 Aug;15(8):823-30
pubmed: 20065955
J Neurol. 1996 Sep;243(9):652-7
pubmed: 8892067
Neuropsychobiology. 2007;55(3-4):132-42
pubmed: 17641545
Arch Med Sci. 2019 Jan;15(1):126-133
pubmed: 30697262
Schizophr Res. 2017 Nov;189:97-103
pubmed: 28139359
Psychiatry Res. 2009 Mar 31;171(3):155-65
pubmed: 19217758
Sci Rep. 2016 Dec 01;6:38152
pubmed: 27905557
Clin Neurophysiol. 2001 Nov;112(11):2138-45
pubmed: 11682353
Schizophr Res. 2015 Dec;169(1-3):109-115
pubmed: 26441005
Schizophr Res. 2010 Dec;124(1-3):91-100
pubmed: 20817483
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Hum Brain Mapp. 2014 Feb;35(2):627-37
pubmed: 23125131
Biol Psychiatry. 2007 May 15;61(10):1148-56
pubmed: 17098213
Cogn Neuropsychol. 2005 Jan 1;22(3):292-305
pubmed: 21038251
Schizophr Res. 2002 Jan 15;53(3):249-61
pubmed: 11738538
Int J Psychiatry Clin Pract. 2015;19(4):228-32
pubmed: 25356661
Br J Psychiatry. 1988 Oct;153:437-43
pubmed: 3074851
Neuroimage. 2002 Oct;17(2):880-9
pubmed: 12377162
Cogn Neuropsychiatry. 2004 Feb-May;9(1-2):43-72
pubmed: 16571574
Neuroscience. 2018 Dec 15;395:60-88
pubmed: 30414881
Schizophr Res. 2018 Dec;202:149-157
pubmed: 30539766
Arch Gen Psychiatry. 2000 Nov;57(11):1033-8
pubmed: 11074868
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1938-43
pubmed: 21840364
Curr Opin Psychiatry. 2009 Mar;22(2):131-9
pubmed: 19553866
Am J Psychiatry. 2000 Oct;157(10):1691-3
pubmed: 11007729
Hum Brain Mapp. 2015 Nov;36(11):4317-33
pubmed: 26308973
Neuropsychologia. 2006;44(12):2578-81
pubmed: 16750545
Am J Psychiatry. 2002 Jul;159(7):1093-102
pubmed: 12091184
Hum Brain Mapp. 1999;7(4):254-66
pubmed: 10408769
Harv Rev Psychiatry. 2005 Sep-Oct;13(5):280-99
pubmed: 16251167
Schizophr Res. 2006 Jan 1;81(1):41-5
pubmed: 16314076
Front Psychiatry. 2019 Mar 29;10:135
pubmed: 30984036
Cereb Cortex. 2000 Aug;10(8):802-8
pubmed: 10920051
Brain. 1993 Feb;116 ( Pt 1):1-20
pubmed: 8453452
Exp Brain Res. 1997 Jul;115(3):430-44
pubmed: 9262198
J Clin Neurosci. 2020 Sep;79:154-159
pubmed: 33070887
Schizophr Res. 2017 Jul;185:122-129
pubmed: 28041917
Neuroimage. 2012 Sep;62(3):1510-9
pubmed: 22659477
Brain. 2004 Oct;127(Pt 10):2307-15
pubmed: 15292055
Nature. 1995 Nov 9;378(6553):176-9
pubmed: 7477318
Arch Gen Psychiatry. 2003 Jan;60(1):49-56
pubmed: 12511172
Br J Psychiatry. 2010 Mar;196(3):206-11
pubmed: 20194543
Biol Psychiatry. 2012 Mar 15;71(6):e15-6
pubmed: 22071532
Biol Psychiatry. 2005 Jul 15;58(2):97-104
pubmed: 15936729
Schizophr Res. 2007 Jul;93(1-3):221-8
pubmed: 17478080
Am J Psychiatry. 1990 Nov;147(11):1457-62
pubmed: 2221156
Radiology. 2016 Jun;279(3):867-75
pubmed: 27007945
Nature. 2001 Jun 21;411(6840):950-3
pubmed: 11418859
Neuroimage. 2005 Apr 15;25(3):653-60
pubmed: 15808966
Biol Psychiatry. 2013 Mar 15;73(6):518-24
pubmed: 22840762
Neuroimage. 2004 Oct;23(2):534-41
pubmed: 15488402
Ann N Y Acad Sci. 2008 Mar;1124:1-38
pubmed: 18400922
Brain Stimul. 2008 Apr;1(2):106-11
pubmed: 20633377
Dialogues Clin Neurosci. 2013 Sep;15(3):339-49
pubmed: 24174905
Schizophr Res. 2000 Jan 21;41(2):303-12
pubmed: 10708339
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:105-113
pubmed: 28442422
Brain Struct Funct. 2013 Jul;218(4):943-50
pubmed: 22790785
Neuropsychologia. 2002;40(2):212-22
pubmed: 11640943
CNS Spectr. 2021 Aug;26(4):319-325
pubmed: 31918770
Neurology. 2000 Apr 11;54(7):1529-31
pubmed: 10751273
Schizophr Bull. 2017 Mar 1;43(2):389-396
pubmed: 27421792
Am J Psychiatry. 2004 Mar;161(3):480-9
pubmed: 14992974
J Neural Transm (Vienna). 2016 Dec;123(12):1479-1490
pubmed: 27503083
Lancet. 1993 Sep 18;342(8873):703-6
pubmed: 8103821
J Clin Psychiatry. 2007 Mar;68(3):416-21
pubmed: 17388712